Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis

BMC Musculoskeletal Disorders

Volumn 14, Issue , 2013, Pages

  Andersson, Maria L E ^a   Svensson, Björn ^b   Petersson, Ingemar F ^b   Hafström, Ingiäld ^c   Albertsson, Kristina ^c   Forslind, Kristina ^b,d   Heinegård, Dick ^b   Saxne, Tore ^b  

^a Spenshult Hospital   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d HELSINGBORG HOSPITAL   (Sweden)

Author keywords

Biomarkers; Cartilage oligomeric matrix protein; COMP; Radiographic joint damage progression; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; CARTILAGE OLIGOMERIC MATRIX PROTEIN; PREDNISOLONE; RHEUMATOID FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; DAS28; DISEASE COURSE; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HAND RADIOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; RHEUMATOID ARTHRITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; ARTHROGRAPHY; BIOLOGICAL MARKERS; DISEASE PROGRESSION; EARLY DIAGNOSIS; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GLYCOPROTEINS; HUMANS; JOINTS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84880950076     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-14-229     Document Type: Article

References (46)

1. Predictors for remission in rheumatoid arthritis patients: A systematic review. Katchamart W, Johnson S, Lin HJ, Phumethum V, Salliot C, Bombardier C, Arthritis Care Res (Hoboken) 2010 62 1128 1143 10.1002/acr.20188
2. Joint damage and disability in rheumatoid arthritis: an updated systematic review. Scott DL, Smith C, Kingsley G, Clin Exp Rheumatol 2003 21 20 S27 14969046
3. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL, Arthritis Rheum 2001 44 2009 2017 10.1002/1529-0131(200109)44:9<2009::AID-ART349>3.0.CO;2-L 11592361 (Pubitemid 33644042)
4. Relationship between inflammation and joint destruction in early rheumatoid arthritis: a mathematical description. Wick MC, Lindblad S, Klareskog L, Van Vollenhoven RF, Ann Rheum Dis 2004 63 848 852 10.1136/ard.2003.015172 15194582 (Pubitemid 38850458)
5. Laboratory tests to assess patients with rheumatoid arthritis: advantages and limitations. Pincus T, Sokka T, Rheum Dis Clin North Am 2009 35 731 734 vi-vii 10.1016/j.rdc.2009.10.007 19962617
6. Complexities in assessment of rheumatoid arthritis: absence of a single gold standard measure. Pincus T, Yazici Y, Sokka T, Rheum Dis Clin North Am 2009 35 687 697 10.1016/j.rdc.2009.10.002 19962613
7. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Sokka T, Toloza S, Cutolo M, Kautiainen H, Makinen H, Gogus F, Skakic V, Badsha H, Peets T, Baranauskaite A, et al. Arthritis Res Ther 2009 11 7 19144159
8. Diagnostic and prognostic value of antibodies and soluble biomarkers in undifferentiated peripheral inflammatory arthritis: a systematic review. Schoels M, Bombardier C, Aletaha D, J Rheumatol Suppl 2011 87 20 25 10.3899/jrheum.101070 21364052
9. Cartilage matrix proteins. An acidic oligomeric protein (COMP) detected only in cartilage. Hedbom E, Antonsson P, Hjerpe A, Aeschlimann D, Paulsson M, Rosa-Pimentel E, Sommarin Y, Wendel M, Oldberg A, Heinegard D, J Biol Chem 1992 267 6132 6136 1556121
10. Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. Saxne T, Heinegard D, Br J Rheumatol 1992 31 583 591 10.1093/rheumatology/31.9.583 1381980
11. Serum concentrations of cartilage oligomeric matrix protein, fibrinogen and hyaluronan distinguish inflammation and cartilage destruction in experimental arthritis in rats. Larsson E, Erlandsson Harris H, Lorentzen JC, Larsson A, Mansson B, Klareskog L, Saxne T, Rheumatol (Oxford) 2002 41 996 1000 10.1093/rheumatology/41.9.996
12. Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept. Crnkic M, Mansson B, Larsson L, Geborek P, Heinegard D, Saxne T, Arthritis Res Ther 2003 5 181 R185 10.1186/ar760 12823852
13. Value of serum cartilage oligomeric matrix protein as a prognostic marker of large-joint damage in rheumatoid arthritis-data from the RAPIT study. de Jong Z, Munneke M, Vilim V, Zwinderman AH, Kroon HM, Ronday HK, Lems WF, Dijkmans BA, Breedveld FC, Vliet Vlieland TP, et al. Rheumatol (Oxford) 2008 47 868 871 10.1093/rheumatology/ken052 (Pubitemid 351796375)
14. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T, Ann Rheum Dis 2005 64 196 201 10.1136/ard.2003.019992 15458956 (Pubitemid 40193611)
15. Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. Mansson B, Carey D, Alini M, Ionescu M, Rosenberg LC, Poole AR, Heinegard D, Saxne T, J Clin Invest 1995 95 1071 1077 10.1172/JCI117753 7533784
16. Cartilage oligomeric matrix protein level in rheumatic diseases: potential use as a marker for measuring articular cartilage damage and/or the therapeutic efficacy of treatments. Morozzi G, Fabbroni M, Bellisai F, Pucci G, Galeazzi M, Ann N Y Acad Sci 2007 1108 398 407 10.1196/annals.1422.041 17894003 (Pubitemid 47528752)
17. Relationship between serum cartilage oligomeric matrix protein levels and disease progression in osteoarthritis of the knee joint. Sharif M, Saxne T, Shepstone L, Kirwan JR, Elson CJ, Heinegard D, Dieppe PA, Br J Rheumatol 1995 34 306 310 10.1093/rheumatology/34.4.306 7788143
18. Biochemical markers of bone and cartilage remodeling in prediction of longterm progression of knee osteoarthritis. Bruyere O, Collette JH, Ethgen O, Rovati LC, Giacovelli G, Henrotin YE, Seidel L, Reginster JY, J Rheumatol 2003 30 1043 1050 12734904 (Pubitemid 36529629)
19. Tissue-derived macromolecules and markers of inflammation in serum in early rheumatoid arthritis: relationship to development of joint destruction in hands and feet. Fex E, Eberhardt K, Saxne T, Br J Rheumatol 1997 36 1161 1165 10.1093/rheumatology/36.11.1161 9402859
20. Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression. Syversen SW, Goll GL, van der Heijde D, Landewe R, Gaarder PI, Odegard S, Haavardsholm EA, Kvien TK, J Rheumatol 2009 36 266 272 10.3899/jrheum.080180 19132792
21. Serum concentrations of cartilage oligomeric matrix protein and bone sialoprotein in hip osteoarthritis: a one year prospective study. Conrozier T, Saxne T, Fan CS, Mathieu P, Tron AM, Heinegard D, Vignon E, Ann Rheum Dis 1998 57 527 532 10.1136/ard.57.9.527 9849311 (Pubitemid 28474059)
22. Serum biologic markers as predictors of disease progression in osteoarthritis of the knee. Georges C, Vigneron H, Ayral X, Listrat V, Ravaud P, Dougados M, Sharif M, Dieppe P, Saxne T, Arthritis Rheum 1997 40 590 591 10.1002/art.1780400333 9082954 (Pubitemid 27123683)
23. Changes in cartilage and bone metabolism identified by serum markers in early osteoarthritis of the knee joint. Petersson IF, Boegard T, Svensson B, Heinegard D, Saxne T, Br J Rheumatol 1998 37 46 50 10.1093/rheumatology/37.1.46 9487250
24. The heritable determinants of cartilage oligomeric matrix protein. Williams FM, Andrew T, Saxne T, Heinegard D, Spector TD, MacGregor AJ, Arthritis Rheum 2006 54 2147 2151 10.1002/art.21931 16802351 (Pubitemid 44051070)
25. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. Arthritis Rheum 1988 31 315 324 10.1002/art.1780310302 3358796 (Pubitemid 18091653)
26. Remission and response to early treatment of RA assessed by the Disease Activity Score. BARFOT study group. Better Anti-rheumatic Farmacotherapy. Svensson B, Schaufelberger C, Teleman A, Theander J, Rheumatol (Oxford) 2000 39 1031 1036 10.1093/rheumatology/39.9.1031
27. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Prevoo ML, Hof MA V 't, Kuper HH, Van Leeuwen MA, Van de Putte LB, Van Riel PL, Arthritis Rheum 1995 38 44 48 10.1002/art.1780380107 7818570
28. DAS remission cut points. Fransen J, van Riel PL, Clin Exp Rheumatol 2006 24 29 32
29. Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. Landewe R, van der Heijde D, van der Linden S, Boers M, Ann Rheum Dis 2006 65 637 641 10.1136/ard.2005.039859 16219709
30. American college of rheumatology/european league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, et al. Ann Rheum Dis 2011 70 404 413 10.1136/ard.2011.149765 21292833
31. Assessing disability in patients with rheumatoid arthritis. Use of a Swedish version of the Stanford Health Assessment Questionnaire. Ekdahl C, Eberhardt K, Andersson SI, Svensson B, Scand J Rheumatol 1988 17 263 271 10.3109/03009748809098795 3187457
32. Biological variation of Cartilage Oligomeric Matrix Protein (COMP): A proposal to interpret laboratory serial testing. Brescia V, Tampoia M, Clin Chim Acta 2007
33. Integration of data derived from biological variation into the quality management system. Ricos C, Alvarez V, Cava F, Garcia-Lario JV, Hernandez A, Jimenez CV, Minchinela J, Perich C, Simon M, Clin Chim Acta 2004 346 13 18 10.1016/j.cccn.2004.03.022 15234631 (Pubitemid 38952685)
34. The reference change value: a proposal to interpret laboratory reports in serial testing based on biological variation. Ricos C, Cava F, Garcia-Lario JV, Hernandez A, Iglesias N, Jimenez CV, Minchinela J, Perich C, Simon M, Domenech MV, Alvarez V, Scand J Clin Lab Invest 2004 64 175 184 10.1080/00365510410004885 15222627 (Pubitemid 38803101)
35. Within-subject biological variation in disease: collated data and clinical consequences. Ricos C, Iglesias N, Garcia-Lario JV, Simon M, Cava F, Hernandez A, Perich C, Minchinela J, Alvarez V, Domenech MV, et al. Ann Clin Biochem 2007 44 343 352 10.1258/000456307780945633 17594781 (Pubitemid 351724670)
36. How to read radiographs according to the Sharp/van der Heijde method. van der Heijde D, J Rheumatol 2000 27 261 263 10648051 (Pubitemid 30058662)
37. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafstrom I, Arthritis Rheum 2005 52 3360 3370 10.1002/art.21298 16255010 (Pubitemid 41612202)
38. Radiographic progression and remission rates in early rheumatoid arthritis-MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Hetland ML, Stengaard-Pedersen K, Junker P, Ostergaard M, Ejbjerg BJ, Jacobsen S, Lottenburger T, Hansen I, Tarp U, Andersen LS, et al. Ann Rheum Dis 2010 69 1789 1795 10.1136/ard.2009.125534 20444751
39. Proteoglycans and more-from molecules to biology. Heinegard D, Int J Exp Pathol 2009 90 575 586 10.1111/j.1365-2613.2009.00695.x 19958398
40. Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing. Smolen JS, van der Heijde DM, Aletaha D, Xu S, Han J, Baker D, St Clair EW, Ann Rheum Dis 2009 68 1535 1540 10.1136/ard.2008.094128 18957487
41. Inflammatory patterns in rheumatoid arthritis estimated by the number of swollen and tender joints, the erythrocyte sedimentation rate, and hemoglobin: longterm course and association to radiographic progression. Graudal N, Tarp U, Jurik AG, Galloe AM, Garred P, Milman N, Graudal HK, J Rheumatol 2000 27 47 57 10648017 (Pubitemid 30058628)
42. Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Plant MJ, Williams AL, O'Sullivan MM, Lewis PA, Coles EC, Jessop JD, Arthritis Rheum 2000 43 1473 1477 10.1002/1529-0131(200007)43:7<1473::AID-ANR9>3.0.CO;2-N 10902748 (Pubitemid 30452464)
43. Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study. Hafstrom I, Albertsson K, Boonen A, van der Heijde D, Landewe R, Svensson B, Ann Rheum Dis 2009 68 508 513 10.1136/ard.2008.087833 18420939
44. Corticosteroid treatment of experimental arthritis retards cartilage destruction as determined by histology and serum COMP. Larsson E, Erlandsson Harris H, Larsson A, Mansson B, Saxne T, Klareskog L, Rheumatol (Oxford) 2004 43 428 434 10.1093/rheumatology/keh073 (Pubitemid 38489358)
45. Serum levels of cartilage oligomeric matrix protein (COMP): a rapid decrease in patients with active rheumatoid arthritis undergoing intravenous steroid treatment. Skoumal M, Haberhauer G, Feyertag J, Kittl EM, Bauer K, Dunky A, Rheumatol Int 2006 26 1001 1004 10.1007/s00296-006-0117-4 16485108 (Pubitemid 44394502)
46. Changes of cartilage and bone markers after intra-articular glucocorticoid treatment with and without postinjection rest in patients with rheumatoid arthritis. Weitoft T, Larsson A, Saxne T, Ronnblom L, Ann Rheum Dis 2005 64 1750 1753 10.1136/ard.2004.035022 15843449 (Pubitemid 41667150)